Collaboration Now: Maximizing AI’s Potential in the Industry it Matters Most
No passing fad, AI in healthcare is here, and it’s already improving the lives of patients, healthcare workers, and researchers. How can we make a good thing even better?
Healthcare Leaders Must Come Together to Mitigate ChatGPT Risks, Experts Urge
The healthcare sector has been notoriously slow to adopt new technologies in the past, but ChatGPT has already begun to enter the field. Technology experts at the HIMSS conference in Chicago said that while the AI model is certainly exciting, the healthcare sector must establish an accountability framework for it's going to address the risks of new technologies like ChatGPT moving forward.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
FDA faces big questions as it takes a closer look at AI regulations
An action plan shared by the FDA earlier this year showed how the regulator is thinking about future regulations for AI and machine learning in healthcare. But the agency still has several big questions to address as it prepares to roll out new guidance.
Analysts grill Novartis execs amid gene therapy data manipulation scandal
Novartis CEO Vas Narasimhan said the data manipulation issue was confined to a disused potency assay for use in mice and predated the company's acquisition of AveXis, while trying to reassure analysts that the disclosure delay was for the sake of completing an internal investigation.
Price made dozens of health stock trades even as committee was investigated
Craig Holman, government affairs lobbyist with Public Citizen, described Price’s volume of stock trades during the SEC inquiry as “brazen,” given the congressman’s access to nonpublic information affecting the companies’ fortunes.
At least 6 senators grilling HHS nominee Tom Price also hold healthcare stocks
At least six members of the two Senate committees tasked with questioning or confirming Tom Price for HHS secretary hold shares in healthcare companies — such as Merck, Medtronic and Gilead — according to a Kaiser Health News analysis.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Tom Price’s top backer told employees to give to PAC
The PAC was operated by Georgia-based MiMedx, whose CEO Parker H. “Pete” Petit is among the top individual contributors to Price. Federal election law prohibits corporations from coercing employees to contribute to PACs.
Australian biotech company offered sweetheart investment deal to Tom Price
Price told HHS ethics officials Thursday that if appointed to be HHS secretary, he will divest himself of the Australian stock as well as stock in about 40 other companies that could pose conflicts.
In Congress, HHS nominee Tom Price intervened for healthcare donors
Price has been a go-to congressman, a review of his records show, for medical special interests hotly sparring with regulators or facing budget cuts.
Verily faces ethics questions over research at CEO’s clinic
Verily also is getting called out for selling data on research volunteers to pharma companies.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Infographic: The rise of CRISPR gene editing, and how it works
A timeline of how CRISPR - an inexpensive and fast-working technology - came into being. These infographics also show the patent work and funding behind CRISPR - and how gene editing could impact a wider population.